Breast Tumor Articles & Analysis
16 news found
The study, which enrolled 194 eligible patients, is the largest controlled multicenter clinical trial ever performed in the U.S. for LN2 based cryoablation of small, low-risk, early-stage malignant breast tumors as an alternative to surgery Dr. Tomkovich commented, “The inclusion of the ICE3 clinical trial interim results as part of the scientific program ...
PathPresenter, a pioneer in the development of digital pathology software, and 4D Path Inc., developer of a pan-cancer diagnostic and precision oncology platform enabling AI-based biomarker typing and prognostication from H&E images, are announcing today a global partnership to distribute 4D Q-plasia OncoReader Breast within PathPresenter’s new Clinical Workflow ...
PHILADELPHIA, March 08, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing small molecule and immunotherapy treatments for breast and gynecological cancers, today announced that five abstracts have been selected for poster or symposium presentations at the American Association for ...
Approximately 300 patients undergoing breast conservation surgery across eight U.S. clinical sites are expected to participate in the pivotal trial, with study completion anticipated by the end of 2022. ...
Invenia ABUS 2.0 is the first FDA-approved Ultrasound supplemental breast screening technology specifically designed for detecting cancer in dense breast tissue. ...
The independent study conducted at the St. Marianna University Breast & Imaging Center, Kawasaki City, Japan enrolled eight female patients, 53 – 72 years-old mean age 62 years, diagnosed with invasive ductal carcinoma (IDC) tumors. Percutaneous ultrasound-guided cryoablation of the breast tumor was performed using ...
(NASDAQ: ICCM) (TASE: ICCM) (“IceCure” or the “Company”), developer of the next generation minimally invasive cryoablation technology that destroys tumors by freezing, today announced that the first peer reviewed article “Cryoablation Without Excision for Low-Risk, Early-Stage Breast Cancer: 3-Year Interim Analysis of Ipsilateral ...
Exact Sciences today announced that its Oncotype DX Breast Recurrence Score test has been recognised as the only test that can be used for prediction of chemotherapy benefit in early-stage breast cancer patients with 1-3 positive axillary lymph nodes, including micro metastases, by the National Comprehensive Cancer Network (NCCN)ii in its updated guidelines for ...
First results from the independent SWOG Cancer Research Network-led Phase III study to be presented at the 2020 San Antonio Breast Cancer Symposium RxPONDER results from over 5,000 women likely to transform the treatment of node-positive breast cancer, as the TAILORx study did in node-negative disease Exact Sciences Corp. (NASDAQ: EXAS) today announced that data from the Rx for Positive ...
SEATTLE, Dec. 09, 2020 (GLOBE NEWSWIRE) -- SEngine Precision Medicine, a precision oncology company revolutionizing cancer therapies by pre-testing drugs on patient-derived tumor organoids, today presented data from a study summarizing the predictive value of the PARIS® Test in breast cancer tumors as a poster session (PS04/01) at the 2020 ...
The presentation is entitled “STACT: A Novel Therapeutic Platform that Delivers Immunomodulatory Payloads to Tumor-Resident Myeloid Cells After IV Dosing and Demonstrates Potent Anti-Tumor Efficacy in Preclinical Studies”. ...
This technology might not only help physicians better differentiate between benign and malignant breast lesions, but also discriminate between breast cancer molecular subtypes. ...
A publication in Photoacoustics describing how OA/US imaging combined with US enables functional and anatomic mapping of the breast.[3] The authors conclude that the OA/US co-registration technology enables increased accuracy of radiologist assessment of malignancy by confirming, upgrading and/or downgrading US BI-RADS categorization of breast ...
Our ability to cause intracellular acidification in cancer cells has the potential to kill any tumor type in a precise manner without producing systemic side effects. ...
Mountford and her team at the University of Newcastle in their pioneering research on novel in vivo NMR techniques that may help identify breast cancer in high-risk women. Preliminary data suggest that NMR may detect early changes in breast tissue that reflect rapid tumor growth. Moreover, NMR may be used to analyze primary ...
For example, cancerous breast cells can spread to a lung and form a new breast cancer tumor there. ...